Form 4: Rapport Therapeutics Director Ramiro Sanchez Acquires Stock Options
SEC Form 4 Filing
Director Ramiro Sanchez acquired stock options in Rapport Therapeutics, Inc. on November 7, 2024.
Summary
- Ramiro Sanchez, a director of Rapport Therapeutics, Inc., acquired 29,756 stock options on November 7, 2024.
- The exercise price of the options is $26.9.
- The options vest over time, with one-third vesting on November 7, 2025, and the remaining shares vesting in 24 equal monthly installments thereafter, contingent upon continued service.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing, so the sentiment is neutral.
Positives
- The acquisition of stock options by a director signals confidence in the company's future prospects.
Industry Context
Form 4 filings are standard practice and provide transparency into insider transactions, allowing investors to track the actions of company directors and officers.
Stakeholder Impact
- Shareholders may view the director's stock option acquisition as a positive sign.
Key Dates
| Date | Description |
|---|---|
| 11/07/2024 | Date of transaction: Ramiro Sanchez acquired stock options. |
| 11/07/2025 | One-third of the acquired stock options vest. |
| 11/07/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.